Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.
Stocks · News reference
TD Cowen Maintains Hold on Ginkgo Bioworks Holdings, Raises Price Target to $11
TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Hold and raises the price target from $9 to $11.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
What's Going on With Ginkgo Bioworks Stock on Friday?
Ginkgo Bioworks offers remote autonomous lab access to NSF X-Labs and integrates Araceli imaging into its Boston platform.
Ginkgo Bioworks shares are trading higher after the company announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program.